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Purpose: To estimate the 5-year incidence and progression of diabetic retinopathy (DR) among persons with
type 2 diabetes mellitus (DM).
Design: Population-based, prospective, cohort study.
Participants: The RETINODIAB (Study Group for Diabetic Retinopathy Screening) program was imple-
mented in the Lisbon and Tagus Valley area between July 2009 and December 2014. A total of 109 543 readable
screening examinations were performed and corresponded to 56 903 patients who attended the screening
program at entry. A total of 30 641 patients (53.85%) had at least 1 further screening event within the study period
and were included in the analysis.
Methods: Participants underwent two 45 nonstereoscopic retinal digital photographs per eye according to
RETINODIAB protocol. All images were graded according to the International Clinical Diabetic Retinopathy Scale.
Referable diabetic retinopathy (RDR) was deﬁned for all patients graded as moderate nonproliferative DR (NPDR),
severe NPDR, or proliferative DR (PDR), with or without maculopathy or mild NPDR with maculopathy.
Nonparametric estimates of the annual and cumulative incidences were obtained by Turnbull’s estimator. As-
sociations between the potential risk factors and the time to onset/progression of retinopathy were assessed
through a parametric survival analysis for interval-censored data.
Main Outcome Measures: The authors estimated the onset and progression incidence rates of DR.
Results: Yearly incidence of any DR in patients without retinopathy at baseline was 4.60% (95% conﬁdence
interval [CI], 3.96e4.76) in the ﬁrst year, decreasing to 3.87% (95% CI, 2.57e5.78) in the ﬁfth year. In participants
with mild NPDR at baseline, the progression rate to RDR in year 1 was 1.18% (95% CI, 0.96e1.33). Incidence of
any DR and RDR and DR progression rate were associated with known duration of diabetes, age at diagnosis,
and use of insulin treatment.
Conclusions: This longitudinal epidemiologic study provides the ﬁrst Portuguese incidence DR data in a
large-scale population-based cohort of type 2 diabetes after a 5-year follow-up. Duration of diabetes, age at
diagnosis, and insulin treatment were associated with increasing risk of incidence and progression of DR. A
personalized schedule distribution of screening intervals according to the individual patient’s proﬁle should be
implemented, with resulting beneﬁts in terms of health costs. Ophthalmology 2015;122:2473-2481 ª 2015 by the
American Academy of Ophthalmology.Diabetic retinopathy (DR) remains a major cause of visual
impairment and represents an ongoing and worrying
worldwide public health issue.1e3 In 2013, 382 million
people had diabetes; this number is expected to increase to
592 million by 2035, according to the International Diabetes
Federation.4 Most people with diabetes live in low- and
middle-income countries, and these will experience the
greatest increase in cases of diabetes over the next 22 years.5
Diabetic retinopathy is a highly speciﬁc vascular compli-
cation of both type 1 and 2 diabetes, with incidence strongly
related to the duration of diabetes.6e8 It is well established that 2015 by the American Academy of Ophthalmology
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and timely treatment of DR among patients with diabetes
mellitus (DM), particularly those with a high risk of DR.9
This type of retinopathy represents an excellent paradigm
for screening as laid out in the principles for screening of
human disease described by Wilson and Jungner in 1968.10
Indeed, from a public health standpoint, screening for DR
has been shown to be cost-effective in health economic
terms.11
To decrease by approximately 30% the new cases of
blindness caused by diabetes, the declaration of St. Vincent2473http://dx.doi.org/10.1016/j.ophtha.2015.08.004
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Ophthalmology Volume 122, Number 12, December 2015(1989) called for the implementation of national strategies
for DR screening in a systematic manner.12 The World
Health Organization, the International Diabetes Federation,
and the Portuguese Directorate-General of Health (DGS)
co-organized in 1997 the Fourth Meeting in Lisbon for the
Implementation of the St. Vincent Declaration, which was
attended by delegates from 60 countries.13 This conference
reinforced, once again, the need for greater engagement
from all signatory countries. This international challenge
was strengthened at the Liverpool meeting in 2005.14
Despite all this, it has been only in the last decade that
signiﬁcant progress has been made in implementing DR
screening programs.
Portugal currently has a population of 10.6million, who are
predominantly white, and the majority (w8.5 million)
are located on the western coast.15 According to the
National Observatory for Diabetes, approximately 1 million
Portuguese have diabetes, the equivalent of 13% of the
population aged 20 to 79 years (2013).16
After a pilot regional DR screening program that was
launched in 2008, the Diabetic Retinopathy Screening Ser-
vice for Lisbon and Tagus Valley, RETINODIAB, was
commissioned and driven by the Portuguese Diabetes As-
sociation (APDP) in 2009. This screening program was
supported by the Regional Health Administration of Lisbon
and Tagus Valley under the auspices of the DGS, which is a
public health branch of the Ministry of Health. The major
aim of this project was to identify all undiagnosed sight-
threatening DR to ensure timely onward referral to Lisbon
area hospital eye services.
The APDP is the world’s oldest diabetes association and
a senior member of the International Diabetes Federation.
Since its foundation in 1926, the APDP has been driven by a
single overarching objective: to improve the quality of life
of people with diabetes.
In Portugal, so far, there are no accurate data on the inci-
dence of DR, based on a large-scale screening community-
based program, over a period of time.
We describe the ﬁrst incidence and progression study for
DR in a Portuguese population among persons with type 2
DM. We estimated the annual and cumulative DR incidence
and the DR rate progression over a 5-year period, and
explored the association between the development of reti-
nopathy and its putative risk factors.Methods
The RETINODIAB Network
RETINODIAB (Study Group for Diabetic Retinopathy Screening)
is a telemedical screening system carried out by the APDP that has
focused on clinical aspects of DR screening. Its primary aim was to
promote the advance of knowledge on all aspects of DR through an
active cooperation between ophthalmologists and other specialists,
such as endocrinologists, internists, and neurologists. Currently,
more than 200,000 people nationwide have beneﬁted from inte-
grated and specialized healthcare services provided by the APDP in
a range of diabetes-related ﬁelds: diabetology, ophthalmology,
pediatrics, nutrition, cardiology, podiatry, nephrology, urology,
women’s health, and mental health.2474
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of Lisbon and the Tagus Valley protocol (Portuguese Ministry of
Health), the Association’s clinical services were integrated into
the public healthcare network around Lisbon and Tagus Valley.
Moreover, the APDP has fostered the development of
important scientiﬁc studies in epidemiology and diabetology in
Portugal.17e19 The APDP has carried out relevant scientiﬁc work
in collaboration with international institutions of reference.
Lisbon and Tagus Valley Area
Lisbon and Tagus Valley is 1 of the 5 regions of Portugal termed
as “Nomenclature of Territorial Units for Statistics” (NUTS II
subdivisions). The region corresponds to 13% of the Portuguese
territory including the capital, Lisbon; it has a population of 3.7
million (34% of the total population); and, according to the Centre
for Regional Dynamics Observation (2009), it represents 44% of
the national gross domestic product.
There are 15 primary health center groups in this area, orga-
nized according to the 5 existing NUTS III (subregions: Greater
Lisbon, Setubal Peninsula, Middle Tagus, Lezíria, and West
Coast). Their mission is to ensure the provision of Primary Health
Care in a particular geographic area, enhancing health gains
accomplished by Family Health Units or other primary care units.
Nonmydriatic Digital Camera for Diabetic
Retinopathy Screening
Currently, teleophthalmology based on digital imaging system
provides a credible and efﬁcient DR screening service. Indeed, it
allows a sensitivity of 92% and a speciﬁcity of 90%, thus justifying
its use in terms of cost/beneﬁt and gains to health.20 Furthermore, it
offers several advantages, such as instant photography display,
ease of storage and consultation of iconography available, and a
remote transmission via Internet. The advance of telemedicine in
ophthalmology screening of DR has a broader application,
especially in remote ophthalmologic-assistance areas.
Portuguese Diabetes Association Screening Protocol
The RETINODIAB screening program was held in several health
units covered by the APDP protocol. It encompasses several
screening centers located in the primary care units of 15 primary
health center groups. Each screening center is equipped with a
nonmydriatic camera (model CR-2, Canon, Tokyo, Japan). Persons
with type 2 diabetes who are registered with a general practitioner
in the Lisbon and Tagus Valley area and not already under the care
of hospital eye services for DR-related reasons are required to be
referred to RETINODIAB program. Only patients with no history
of documented DR or mild DR were referred for screening. All
persons invited for examination are sent an appointment letter with
a date, time, and medical center for screening. The devices were
allocateddgeographic distribution among different health
centersdin a regular and systematic manner to improve the
interaction with general practitioners, thus optimizing system
referral and screening. All images were classiﬁed according to The
International Clinical Diabetic Retinopathy Scale.21
This International Clinical Classiﬁcation System categorizes
DR severity in 5 levels, which include 3 stages of low risk (none,
mild, and moderate NPDR), a fourth stage of severe NPDR, and a
ﬁfth stage of PDR, in the presence or absence of diabetic macular
edema, which is graded separately. Referable diabetic retinopathy
(RDR) was deﬁned for all patients graded as moderate NPDR;
severe NPDR or PDR, with or without maculopathy; or mild
NPDR with maculopathy. This category (RDR) relates to thoseentral from ClinicalKey.com by Elsevier on October 24, 2017.
 Copyright ©2017. Elsevier Inc. All rights reserved.
Table 1. Baseline Characteristics of Study Participants
Characteristics 1 Screening Event (n [ 26 262) >1 Screening Event (n [ 30 641) P Value
Age (yrs): median (P25; P75) 70 (62; 77) 70 (62; 77) 0.111
Known duration of DM (yrs): median (P25; P75) 6 (3; 12) 9 (5; 14) <0.001
Age at diagnosis of DM (yrs): median (P25; P75) 61 (52; 69) 61 (54; 69) <0.001
Sex (n; %)
Male 12 982 (49.4) 15 588 (50.9) 0.686
Female 13 280 (50.6) 15 053 (49.1)
Insulin (n; %)
No 25 095 (95.6) 29 259 (95.5) <0.001
Yes 1166 (4.4) 1382 (4.5)
DM ¼ diabetes mellitus.
Dutra Medeiros et al  Diabetic Retinopathy in Portugalwho would, according to the guidelines, need referral to the hos-
pital eye service for further clinical evaluation.
Because clinically signiﬁcant macular edema is not discernible
on nonstereoscopic images, maculopathy was deﬁned as the pres-
ence of hard exudates within 1 disc diameter of the fovea. Patients
found to have undergone panretinal laser treatment were classiﬁed as
having PDR. Both eyes were assessed for DR, and the worse grade
from the 2 eyes was used in the analysis. Digital retinal images were
considered not gradable if the retina of both eyes could not be
visualized properly, that is, retinal vessels were not visible within 1
disc diameter of the fovea and ﬁne vessels were not visible across the
surface of the optic disc.When only 1 eyewas gradable, the presence
or absence of DR relied on this eye and subsequently documented in
RETINODIAB data. The reader automatically generated report
displays of diagnosis of DR level, diagnosis of nondiabetic ocular
disorders, and recommendations for follow-up. After the capture of
images, they are compressed in the Digital Imaging and Commu-
nications in Medicine protocol and transmitted through the Internet
to the central medical server for interpretation and storage. In the
datasheet adjunct to retinography, the following information was
documented: sex, patient age, duration of diabetes, treatment
adopted (by diet, oral hypoglycemic agents, or insulin), metabolic
control analysis by the last value of hemoglobin A1c (when avail-
able), and associated comorbidity.
Individuals having no DR signs in either eye at baseline and
having any DR grade in either of the eyes at 1 of the 5 years of
follow-up were considered incident cases. Progression of DR
occurred for those patients with mild NPDR without maculopathy
and having progressed to moderate or severe NPDR grade, PDR
grade, maculopathy stage, or laser photocoagulation treatment
during follow-up time.Table 2. Baseline Characteristics of Patients A
Characteristics
No Retinopathy
(n [ 48 888)
A
Age (yrs): median (P25; P75) 70 (62; 77)
Known duration of DM (yrs): median (P25; P75) 5 (2; 10)
Age at diagnosis of DM (yrs): median (P25; P75) 62 (54; 70)
Sex (n; %)
Male 24 298 (49.7)
Female 24 590 (50.3)
Insulin (n; %)
No 47 667 (97.5)
Yes 1220 (2.5)
DM ¼ diabetes mellitus.
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All orthoptists involved in the project received a full day
of theoretic teaching and 5 days of practical training that
addressed the operation of the nonmydriatic camera and matching
software.
The retinography was performed in a dark room (a scotopic
environment) to obtain a sufﬁcient mydriasis. Each screening ex-
amination lasted approximately 10 minutes. Two 45 non-
stereoscopic retinal digital photographs per eye were obtained, one
centered on the posterior pole and the other centered on the optic
disc. Good patient compliance and clear optical media were crucial
for obtaining good-quality pictures. Despite all efforts, in several
patients it was impossible to obtain an image with minimum
quality to be evaluated by the ophthalmologist. In these speciﬁc
cases, they proceeded to iatrogenic pupil dilation with a topical
mydriatic. Otherwise, the remaining possible causes for deﬁcient
acquisition of fundus were documented by technicians and pro-
ceeded to onward referral for scheduling with a specialist within a
maximum period of 3 months, according to the protocol.
APDPSoft Software
The APDPSoft is a software developed since 1999 that has
accompanied the evolution of the services provided by the APDP.
Currently, this software supports and monitors a number of va-
lences, especially in terms of clinical data ﬁle, markings manage-
ment, laboratory parameters, invoicing the health subsystems,
integration of numerous pieces of diagnosis equipment, and an
effective liaison with the electronic services of the Ministry of






(n [ 2910) P Value
70 (62; 77) 0.748 70 (63; 76) <0.001
12 (8; 20) <0.001 15 (10; 20) <0.001
55 (47; 63) <0.001 53 (44; 60) <0.001
4272 (53.3) <0.001 1562 (53.7) <0.001
3743 (46.7) 1348 (46.3)
6963 (86.9) <0.001 2397 (82.4) <0.001
1052 (13.1) 513 (17.5)
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1 yr 409 101 4.60 (3.96e4.76) 4.60 (4.35e4.85) 339 1 0.23 (0.13e0.28) 0.23 (0.17e0.28)
2 yrs 1629 246 2.40 (2.17e3.09) 7.00 (6.67e7.34) 1495 31 0.48 (0.36e0.63) 0.71 (0.59e0.83)
3 yrs 4516 643 1.70 (1.10e2.70) 8.71 (8.29e9.11) 4215 42 0.32 (0.07e0.54) 1.03 (0.87e1.19)
4 yrs 6788 530 1.89 (0.63e2.87) 10.59 (10.02e11.16) 6766 67 0.34 (0.09e0.63) 1.37 (1.13e1.60)
5 yrs 13 745 444 3.87 (2.57e5.78) 14.47 (13.01e15.90) 14 272 55 0.002 (0.00e0.04) 1.37 (1.13e1.60)
The 95% CIs for annual incidences were obtained using bootstrap and for cumulative incidences using the function “survﬁt” from the R package “survival.”
n ¼ the number of positive cases in a given time-interval or the number of patients reaching end point.
*To estimate annual and cumulative incidences of onset or progression of DR, nonparametric Turnbull estimator, which takes into account interval-
censored data, had to be applied.
Ophthalmology Volume 122, Number 12, December 2015practitioner and the return of the retinography report, stock images,
and new appointment proposal).
Furthermore, it stores clinical data and fundus photographs, and
provides data to statistical processing. Safe access to the applica-
tion is allowed by the use of a password. The stored images were
downloaded by certiﬁed ophthalmologists at the RETINODIAB
Reading Centre, comprising 3 readers.
Statistical Methods
Characteristics of study participants were described using the
median and interquartile range (P25; P75) for continuous variables
and percentages for categoric variables. The primary end points
were “time to onset” and “time to progression” of DR. The pres-
ence/progression or absence/no progression of DR was determined
after each screening event during the study period. Although it was
supposed to occur annually, screening examination took place at
different periods of time during the 5-year follow-up. For people
who developed retinopathy (or progressed) between 2 screening
events, the time to DR onset (or progression) is set among the 2
instants, and therefore the data are interval censored; for those who
did not develop the disorder (or did not progress) by the ﬁnalTable 4. Yearly Incidence and 95% Conﬁdence Interval of













1 yr 817 34 1.18 (0.96e1.33) 1.18 (1.05e1.30)
2 yrs 2025 94 0.50 (0.26e0.76) 1.68 (1.52e1.85)
3 yrs 6968 164 0.50 (0.22e1.05) 2.18 (1.96e2.40)
4 yrs 7384 162 1.89 (1.18e2.42) 4.07 (3.62e4.52)
5 yrs 13 447 112 0.52 (0.00e1.09) 4.59 (3.74e5.44)
The 95% CIs for annual incidences were obtained using bootstrap and for
cumulative incidences using the function “survﬁt” from the R package
“survival.”
n ¼ the number of positive cases in a given time-interval or the number of
patients reaching end point.
*To estimate annual and cumulative incidences of onset or progression of
DR, nonparametric Turnbull estimator, which takes into account interval-
censored data, had to be applied.
2476
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mate annual and cumulative incidences of onset/progression of
DR, nonparametric Turnbull estimator for interval-censored data
was applied. Bootstrap was used to obtain the 95% conﬁdence
intervals (CIs) for the annual incidences. We proceeded to a
parametric survival analysis using Weibull proportional hazards
regression model for interval-censored data. The aim of this
analysis was to identify the variables that could inﬂuence the
incidence of any retinopathy or RDR or further retinopathy pro-
gression to RDR. For both univariable and multivariable regression
analyses, age at diagnosis and duration of diabetes were catego-
rized into 4 groups: 40e49 years, 50e59 years, 60e69 years, and
70 years, and <5 years, 5e9 years, 10e15 years, and >15 years,
respectively.
Crude and multivariable-adjusted hazard ratios were reported.
A level of signiﬁcance a ¼ 0.05 was considered. All data were
analyzed using STATA 13.0 (StataCorp. 2013. Stata Statistical
Software: Release 13. StataCorp LP, College Station, TX) and R
software (R: A Language and Environment for Statistical
Computing, R Core Team, R Foundation for Statistical Computing,
Vienna, Austria, year ¼ 2014, http://www.R-project.org).
Ethical Approval
Approval was obtained from the APDP ethics committee.Results
The RETINODIAB screening program was implemented by the
APDP in the Lisbon and Tagus Valley area between July 2009 and
December 2014. It included type 2 diabetic patients, diagnosed at
more than 40 years of age. A total of 109 543 readable screening
examinations were performed, which corresponded to 56 903 pa-
tients who attended the screening program at entry.
Overall, not all screening examinations resulted in assessable
images. In this study, retinal photographs of at least 1 eye could not
be graded in 2876 of the 59 779 total screening patient examina-
tions performed at entry (4.81%). This subset of patients was not
included in the ﬁnal group used to calculate several incidence and
progression rates.
There were 48 888 patients (85.9%) who had no DR at baseline
and were at risk of incident DR; therefore, they were eligible for
the 5-year follow-up incidence study. All patients who hadentral from ClinicalKey.com by Elsevier on October 24, 2017.
 Copyright ©2017. Elsevier Inc. All rights reserved.
Table 5. Yearly Incidence and 95% Conﬁdence Interval of Any and Referable Retinopathy in Participants Using Insulin Treatment and
without Retinopathy at Baseline
Time from Last
Negative Screen













1 yr 23 10 12.47 (10.43e14.81) 12.47 (10.33e14.57) 15 0 0.91 (0.00e1.71) 0.91 (0.30e1.51)
2 yrs 60 23 6.67 (1.78e9.27) 19.14 (16.37e21.82) 46 3 2.62 (1.06e4.29) 3.53 (2.19e4.85)
3 yrs 140 57 4.83 (0.33e9.12) 23.97 (20.56e27.23) 108 5 0.002 (0.00e1.40) 3.53 (2.20e4.85)
4 yrs 284 46 0.00 (0.00e6.05) 23.97 (20.56e27.24) 283 13 1.93 (0.00e4.34) 5.46 (3.20e7.67)
5 yrs 432 53 11.81 (4.57e19.97) 35.79 (27.79e42.90) 487 10 0.00 (0.00e0.02) 5.46 (3.20e7.67)
The 95% CIs for annual incidences were obtained using bootstrap and for cumulative incidences using the function “survﬁt” from the R package “survival.”
n ¼ the number of positive cases in a given time-interval or the number of patients reaching end point.
*To estimate annual and cumulative incidences of onset or progression of DR, nonparametric Turnbull estimator, which takes into account interval-
censored data, had to be applied.
Dutra Medeiros et al  Diabetic Retinopathy in Portugalevidence of mild NPDR during the 5-year study period were
eligible to estimate the DR rate progression.
A total of 26 262 patients (46.15%) were screened only once.
Otherwise, 30 641 patients (53.85%) had at least 1 further
screening event within the study period and were included in the
analysis. In addition, we found that 14 677 participants (25.8%)
had a third screening event, 6042 patients (10.63%) had a fourth
screening event, and 1151 patients (2.03%) had a ﬁfth screening
event, corresponding to 83 152 examinations performed. It was not
possible to verify whether the nonattending patients had undergone
ophthalmological examination elsewhere during the follow-up.
The baseline characteristics of study participants at risk of
incidence or progression of DR are shown in Tables 1 and 2.
Table 3 shows the annual and cumulative incidence for
development of any retinopathy and RDR for patients without
retinopathy at baseline. Yearly incidence of any DR in patients
without retinopathy at baseline was 4.60% (95% CI, 3.96e4.76)
in the ﬁrst year, decreasing to 3.87% (95% CI, 2.57e5.78) in the
ﬁfth year; the cumulative incidence at 5 years was 14.47% (95%
CI, 13.01e15.90).Table 6. Yearly Incidence and 95% Conﬁdence Interval of
Referable Retinopathy in Participants Using Insulin Treatment












1 yr 67 4 4.34 (2.55e5.65) 4.34 (3.21e5.46)
2 yrs 107 19 1.78 (0.28e4.03) 6.12 (4.68e7.53)
3 yrs 265 20 5.82 (0.01e8.33) 11.94 (9.30e14.50)
4 yrs 428 35 2.96 (0.00e8.54) 14.90 (11.64e18.03)
5 yrs 515 25 0.00 (0.00e0.00) 14.90 (11.64e18.03)
The 95% CIs for annual incidences were obtained using bootstrap and for
cumulative incidences using the function “survﬁt” from the R package
“survival.”
n ¼ the number of positive cases in a given time-interval or the number of
patients reaching end point.
*To estimate annual and cumulative incidences of onset or progression of
DR, nonparametric Turnbull estimator, which takes into account interval-
censored data, had to be applied.
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0.13e0.28), decreasing to 0.002% (95% CI, 0.00e0.04) in the ﬁfth
year, with a cumulative incidence of 1.37% (95% CI, 1.13e1.60).
In participants with mild NPDR at baseline, the progression rate
to RDR in the ﬁrst year was 1.18% (95% CI, 0.96e1.33) and
0.52% (95% CI, 0.00e1.09) in the ﬁfth year, with a cumulative
incidence of 4.59% (95% CI, 3.74e5.44) to higher grades of
retinopathy after 5 years (Table 4).
In the subgroup of patients under insulin treatment and without
retinopathy at baseline, the yearly incidence of any retinopathy was
12.47% (95% CI, 10.43e14.81) in the ﬁrst year, decreasing to
11.81% (95% CI, 4.57e19.97) in the ﬁfth year (Table 5). The
cumulative incidence at 5 years was 35.79% (95% CI,
27.79e42.90). The yearly progression DR rate was 4.34% (95%
CI, 2.55e5.65) in the ﬁrst year, decreasing to 2.96% (95% CI,
0.00e8.54) in the fourth year in patients receiving insulin
treatment and with minimum retinopathy at entry (Table 6).
Furthermore, the cumulative incidence of DR progression was
14.9% (95% CI, 11.64e18.03) in participants who received
insulin treatment.
Table 7 highlights the effect of known duration of DM, age at
diagnosis of DM, and insulin treatment on the risk of participants
developing any or referable retinopathy. A signiﬁcantly increased
risk of RDR was associated with an increased duration of DM.
All factors were signiﬁcant except for the subgroup of patients
with a known duration of DM between 5 and 9 years for
adjusted RDR. These results show that hazard rate increases over
time; patients diagnosed at less than 50 years of age and with
more than 15 years of diabetes duration are at a higher risk of
developing the disease. An earlier age at diagnosis, a long
duration of diabetes, and insulin treatment had similar effects on
the risk of developing any or referable retinopathy, according to
the different subgroups.
Table 8 refers to the survival analysis considering participants
with mild retinopathy at baseline who developed RDR. All
factors were statistically signiﬁcant, concerning all subgroups
analyzed. A signiﬁcant risk of referral was associated with an
increased duration of DM, with a lower age at diabetes diagnosis
and in the subset of patients receiving insulin therapy in the
5 years analyzed. In this Weibull proportional hazards regression
model, individuals who were diagnosed at baseline with mild
NPDR at <50 years of age were signiﬁcantly more likely to2477
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Table 7. Parametric Survival Analysis Considering Participants without Retinopathy at Baseline Who Developed Any and Referable
Retinopathy
Putative Risk Factor
Any Retinopathy Referable Retinopathy
Crude HR (95% CI) Adjusted HR (95% CI) Crude HR (95% CI) Adjusted HR (95% CI)
Known duration of DM
<5 yrs 1.00 1.00 1.00 1.00
5e9 yrs 1.35 (1.18e1.55) 1.24 (1.08e1.42) 1.77 (1.05e2.98) 1.60 (0.95e2.69)
10e15 yrs 1.77 (1.55e2.03) 1.48 (1.29e1.70) 2.95 (1.79e4.87) 2.33 (1.41e3.86)
>15 yrs 2.81 (2.44e3.25) 2.07 (1.79e2.41) 5.91 (3.57e9.78) 3.87 (2.31e6.48)
Age at diagnosis of DM
70 yrs 1.00 1.00 1.00 1.00
60e69 yrs 1.47 (1.24e1.74) 1.41 (1.19e1.66) 2.39 (1.23e4.62) 2.19 (1.13e4.24)
50e59 yrs 2.61 (2.23e3.05) 2.38 (2.04e2.79) 3.63 (1.92e6.86) 3.04 (1.60e5.76)
<50 yrs 4.26 (3.62e5.02) 3.45 (2.92e4.07) 8.42 (4.45e15.93) 5.66 (2.97e10.80)
Insulin
No 1.00 1.00 1.00 1.00
Yes 2.90 (2.50e3.37) 2.17 (2.92e4.07) 4.49 (3.06e6.60) 3.04 (2.06e4.49)
CI ¼ conﬁdence interval; DM ¼ diabetes mellitus; HR ¼ hazard ratio.
The following parameters were used for adjustment: duration of DM, age at diagnosis of DM, and insulin treatment. All factors were statistically signiﬁcant
except “known duration of DM” between 5 and 9 years for referable retinopathy.
Ophthalmology Volume 122, Number 12, December 2015develop DR compared with individuals who were diagnosed at
70 years of age (adjusted hazard ratio, 4.63; 95% CI, 3.17e6.77).
Discussion
Diabetes has a high prevalence in Portugal. The PRE-
VADIAB study,18 which was carried out by the APDP,
found a diabetes prevalence of 11.7%, with a signiﬁcant
difference between men (14.2%) and women (9.5%).
Although 6.6% of the subjects had previously been
diagnosed with diabetes, 5.1% were undiagnosed. In
addition, the APDP undertook another epidemiologic
study to ascertain DR prevalence in a PortugueseTable 8. Parametric Survival Analysis Considering Participants




Crude HR (95% CI) Adjusted HR (95% CI)
Known duration of DM
<5 yrs 1.00 1.00
5e9 yrs 1.73 (1.26e2.39) 1.52 (1.10e2.10)
10e15 yrs 3.15 (2.32e4.28) 2.41 (1.77e3.28)
>15 yrs 5.83 (4.29e7.93) 3.64 (2.65e4.99)
Age at diagnosis of DM
70 yrs 1.00 1.00
60e69 yrs 1.85 (1.24e2.77) 1.69 (1.13e2.53)
50e59 yrs 4.06 (2.80e5.88) 3.28 (2.26e4.76)
<50 yrs 7.35 (5.06e10.67) 4.63 (3.17e6.77)
Insulin
No 1.00 1.00
Yes 4.34 (3.51e5.38) 2.82 (2.27e3.51)
CI ¼ conﬁdence interval; DM ¼ diabetes mellitus; HR ¼ hazard ratio.
The following parameters were used for adjustment: duration of DM, age at
diagnosis of DM, and insulin treatment. All factors were statistically
signiﬁcant.
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alence of any DR, NRDR, and RDR in type 2 diabetic pa-
tients of 16.3%, 10.4%, and 5.9%, respectively.17
The teleophthalmology network constitutes an efﬁcient
means to overcome the lack of ophthalmologists.19 In
accordance with these statistics, Portugal may have
approximately 1 million people with diabetes, of whom
700 000 are diagnosed and receiving medical treatment and
who should be consulted annually according to the criteria
stated earlier. According to the Portuguese Ophthalmology
Society, each of the 930 Portuguese ophthalmologists might
observe approximately 753 cases per year, an infeasible
number in terms of logistics specialty requirements. Screening
centers or mobile units using nonmydriatic cameras should be
allocated in areas with a high rate of poverty and a low
number of ophthalmologists, such as the West Region,
which is covered by the RETINODIAB program (Fig 1).
Furthermore, the centralization of the network around a
central reading headquarters led to uniformity regarding the
classiﬁcation approach between graders. However, because of
a standard multidisciplinary approach, general practitioners
and endocrinologists could adjust their therapeutics without
delay, when required. Since the publication of the DGS
recommendations for DR screening, we have adopted a
protocol that includes 2 nonmydriatic photographs centered
on the macula and the disc.22
The epidemiologic cohort studies addressing DR inci-
dence have varied worldwide, at least partly because of
different ethnic populations. Although most observational
studies have adopted annual screening protocols, the
screening intervals and strategies for grading retinopathy
have differed, yielding to an inaccurate comparison of the
DR incidence rates among published data.
The long-term incidence of DR was addressed in
several western populations, such as in the Wisconsin
Epidemiologic Study of Diabetic Retinopathy,23 the Fyn
County Study,24 and an English population-based cohort.25entral from ClinicalKey.com by Elsevier on October 24, 2017.
 Copyright ©2017. Elsevier Inc. All rights reserved.
Figure 1. Regional Health Administration of the Lisbon and Tagus Valley geographic area.
Dutra Medeiros et al  Diabetic Retinopathy in PortugalIn the Wisconsin Epidemiologic Study of Diabetic
Retinopathy, Klein et al23 analyzed the progression of
retinopathy in persons with type 1 diabetes after 25 years
of follow-up. They ascertained a 25-year cumulative rate
of DR progression of 83%, a progression to PDR of 42%,
and an improvement of DR of 18%. In addition, the 25-year
cumulative incidence was 29% for macular edema and 17%
for clinically signiﬁcant macular edema.
In England, 20 686 patients with type 2 diabetes without
PDR or sight-threatening maculopathy at baseline have been
followed during a 17-year period.25 After 5 years, few
patients without retinopathy at baseline developed pre-
proliferative retinopathy (cumulative incidence 4.0%),
sight-threatening maculopathy (0.59%), or PDR (0.68%).
After 10 years of follow-up, the respective cumulative in-
cidences were 16.4%, 1.2%, and 1.5%. Among those with
NPDR (background) at baseline, after 5 years 23% developed
pre-proliferative retinopathy, 5.2% developed maculopathy,
and 6.1% developed PDR; after 10 years, the respective cu-
mulative incidences were 53%, 9.6%, and 11%.
The Liverpool Diabetic Eye Study screening program
reported an annual incidence of RDR of 0.2% in the ﬁrst
year, with a cumulative incidence of 1.7% at 4 years.26 The
authors recommended an extension of the screening intervalDownloaded for Anonymous User (n/a) at Centro Hospitalar Lisboa C
For personal use only. No other uses without permission.to triennial screening, based on the 95% probability of
people remaining free from sight-threatening retinopathy
with a mean screening interval of 5.4 years.
Thomas et al27 evaluated the incidence of DR concerning a
Welsh nationalebased diabetic-cohort screening that
included 57 199 people with type 2 diabetes who had no ev-
idence of DR at baseline, over a 4-year period. They reported a
cumulative incidence of any and referable retinopathy at 4
years of 36027 and 11.64 per 1000 people, respectively. In a
Swedish screening program of a cohort with well-controlled
type 2 DM (patients without DR and with mean hemoglobin
A1c 6.4% at baseline), the researchers observed that 28% of
participants developed mild to moderate retinopathy but did
not develop referable retinopathy in the form of severe pre-
proliferative or PDR over a 3-year period.28
In the RETINODIAB cohort, the incidence of any DR in
patients without retinopathy at baseline was 4.60% (95% CI,
3.96e4.76) in the ﬁrst year, decreasing to 3.87% (95% CI,
2.57e5.78) in the ﬁfth year; the cumulative incidence at 5
years was 14.47% (95% CI, 13.01e15.90). The annual
incidence of referable retinopathy at 1 year was 0.23% (95%
CI, 0.13e0.28), increasing to 0.34% (95% CI, 0.09e0.063)
at 4 years, with a cumulative incidence of 1.37% (95% CI,
1.13e1.60).2479
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Ophthalmology Volume 122, Number 12, December 2015In patients with mild NPDR at baseline, the progression
rate to RDR in the ﬁrst year was 1.18% (95% CI,
0.96e1.33) and 0.52% (95% CI, 0.00e1.09) in the ﬁfth
year, with a cumulative incidence of 4.59% (95% CI,
3.74e5.44) to higher grades of retinopathy after 5 years.
The observed yearly and cumulative incident rates of
RETINODIAB cohort were close to those in the previous
published reports, namely, from the Liverpool Diabetic Eye
Study screening program. Furthermore, our study reported
an increasing hazard rate over time, with regard to a longer
duration of diabetes, an earlier age at diagnosis, and under
insulin treatment.
This was reinforced by other studies documenting that the
incidence of DR was associated with a longer duration of
diabetes and a younger age at diagnosis of diabetes.
Although the duration of diabetes is not a modiﬁable risk
characteristic, our ﬁndings might contribute to better man-
agement strategies by suggesting that patients with the fea-
tures described have a higher risk of DR emergence and thus
need more regular screening. This is in accordance with
several studies that advise a customized schedule distribution
of screening intervals according to the individual patient’s
risk.11,29e32 In fact, increasing the length of the screening
intervals for lower-risk cases would involve fewer screening
episodes, with obvious beneﬁts in terms of health costs.
The data from the screening program in Iceland
concluded that biennial screening would be safe in those
people without evidence of DR at ﬁrst screening examina-
tion.31 Therefore, on the basis of the current published
literature, we should note that annual eye examination is
not necessary for all patients with type 2 diabetes.
The main purpose of the RETINODIAB implementation
was to improve DR screening in Lisbon and the Tagus
Valley surrounding area to efﬁciently perform, within an
acceptable time frame, all eye examinations according to the
guidelines of the DGS.21 In addition to its major objective to
provide access to an annual fundus examination to more
diabetic patients, another goal of RETINODIAB network
is to improve the quality of the reports produced.
This longitudinal epidemiologic study provides the ﬁrst
Portuguese incidence DR data in a large-scale population-
based cohort with type 2 diabetes that includes a medium-
term follow-up and several well-controlled risk factors. To
the best of our knowledge, this study represents one of the
largest reported community-based DR screening program
to ascertain the incidence and progression of this disease.
We will continue to follow these patients to better deﬁne
all epidemiologic variables regarding this diabetic
population.
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